ArticleMedeniyet medical journal2026
Evaluation of Hypoxia-Conditioned MSC Exosomes' Effects on GM-CSF and IL-1α Expression in a Rat Model of Androgenic Alopecia.
Article in Medeniyet medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dose-Response Overstatement and Vesicle-Attribution Uncertainty in Hypoxia-Conditioned MSC Exosome Therapy for Androgenetic Alopecia.Medeniyet medical journal · 2026Article
- Extracellular Vesicles for Androgenetic Alopecia: Current Evidence, Mechanisms, and Clinical Prospects.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the effects of hypoxia-conditioned mesenchymal stem cell exosomes (EH-MSCs) on granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-1α (IL-1α) expression in a dihydrotestosterone (DHT)-induced murine model of androgenetic alopecia. Methods: This experimental study employed a randomized posttest-only control-group with 34 male C57BL/6 mice. These mice were divided into five groups: healthy control Group 1 (G1); DHT-induced control receiving saline (G2); DHT-induced mice treated with topical 5% minoxidil (G3); DHT-induced mice treated with EH-MSCs at 100 μg/kgBW (G4); and DHT-induced mice treated with EH-MSCs at 200 μg/kgBW (G5). The MSCs were isolated from umbilical cords, validated based on morphology, surface marker expression, and differentiation assays, and the exosomes were characterized by the presence of CD63 and CD9 markers. Gene expression of GM-CSF and IL-1α was quantified by real-time polymerase chain reaction. Statistical analyses included ANOVA or non-parametric equivalents, with p<0.05 being considered significant. Results: EH-MSC treatment significantly modulated cytokine expression compared with controls. GM-CSF expression was upregulated in EH-MSC groups, with the highest level being found in G5 (3.42±0.31). This showed a dose-dependent effect (p<0.001). Conversely, IL-1α expression was downregulated, with the lowest level being found in G5 (0.95±0.33). This indicated potent anti-inflammatory activity (p=0.001). Finally, minoxidil did not significantly reduce IL-1α levels compared with saline. Conclusions: EH-MSCs increased GM-CSF and decreased IL-1α expression in a dose-dependent manner, demonstrating dual regenerative and anti-inflammatory effects. These findings support the idea that EH-MSCs can serve as a promising therapeutic candidate for androgenetic alopecia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.